Your browser doesn't support javascript.
Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study.
Madelon, Natacha; Lauper, Kim; Breville, Gautier; Sabater Royo, Irène; Goldstein, Rachel; Andrey, Diego O; Grifoni, Alba; Sette, Alessandro; Kaiser, Laurent; Siegrist, Claire Anne; Finckh, Axel; Lalive, Patrice H; Didierlaurent, Arnaud M; Eberhardt, Christiane S.
  • Madelon N; Center for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
  • Lauper K; Department of Medicine, Division of Rheumatology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
  • Breville G; Department of Neurosciences, Division of Neurology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
  • Sabater Royo I; Center for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
  • Goldstein R; Center for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
  • Andrey DO; Department of Diagnostics, Division of Laboratory Medicine; Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
  • Grifoni A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, University of California, San Diego, La Jolla, California, USA.
  • Sette A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA.
  • Kaiser L; Geneva Centre for Emerging Viral Diseases, Division of Infectious Diseases, Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
  • Siegrist CA; Center for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
  • Finckh A; Center for Vaccinology, Geneva University Hospitals and Department of Woman, Child and Adolescent Medicine, Division of General Pediatrics, University of Geneva, Geneva, Switzerland.
  • Lalive PH; Department of Medicine, Division of Rheumatology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
  • Didierlaurent AM; Department of Neurosciences, Division of Neurology, Department of Pathology and Immunology, Geneva University Hospitals and University of Geneva, Geneva, Switzerlandand.
  • Eberhardt CS; Center for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Clin Infect Dis ; 75(1): e1037-e1045, 2022 Aug 24.
Article in English | MEDLINE | ID: covidwho-1522161
ABSTRACT

BACKGROUND:

Patients treated with anti-CD20 therapy are particularly at risk of developing severe coronavirus disease 2019 (COVID-19); however, little is known regarding COVID-19 vaccine effectiveness in this population.

METHODS:

This prospective observational cohort study assesses humoral and T-cell responses after vaccination with 2 doses of mRNA-based COVID-19 vaccines in patients treated with rituximab for rheumatic diseases or ocrelizumab for multiple sclerosis (n = 37), compared to immunocompetent individuals (n = 22).

RESULTS:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies were detectable in only 69.4% of patients and at levels that were significantly lower compared to controls who all seroconverted. In contrast to antibodies, Spike (S)-specific CD4 T cells were equally detected in immunocompetent and anti-CD20 treated patients (85-90%) and mostly of a Th1 phenotype. Response rates of S-specific CD8 T cells were higher in ocrelizumab (96.2%) and rituximab-treated patients (81.8%) as compared to controls (66.7%). S-specific CD4 and CD8 T cells were polyfunctional but expressed more effector molecules in patients than in controls. During follow-up, 3 MS patients without SARS-CoV-2-specific antibody response had a mild breakthrough infection. One of them had no detectable S-specific T cells after vaccination.

CONCLUSIONS:

Our study suggests that patients on anti-CD20 treatment are able to mount potent T-cell responses to mRNA COVID-19 vaccines, despite impaired humoral responses. This could play an important role in the reduction of complications of severe COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 / COVID-19 Drug Treatment Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 / COVID-19 Drug Treatment Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid